SYSTEMIC SCLEROSIS

This early-phase study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy harmful B cells. It aims to see if this approach is safe and tolerable for people with active autoimmune diseases like lupus, scleroderma, and Sjogr…

This early-phase study is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathy that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, which are modified in a lab t…

This study tests an experimental drug called MT-0551 against a placebo in 80 adults with systemic sclerosis, a disease that causes skin thickening and can affect internal organs. The main goal is to see if the drug reduces skin hardening over 26 weeks. Researchers will also check…

This study tests whether anifrolumab, given as a shot under the skin, can help adults with systemic sclerosis (a disease causing skin thickening and organ damage). About 314 people aged 18 to 70 with early-stage disease will receive either the drug or a placebo. The goal is to se…

This study tests a new treatment using donor immune cells (CAR T-cells) that are designed to target and destroy faulty immune cells causing lupus and scleroderma. The goal is to control these severe autoimmune diseases when other treatments have failed. 18 adults with relapsed or…

This study looks at whether giving people with inflammatory arthritis a list of community resources, a community specialist, or a nurse navigator can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in t…

This study looks at whether artificial intelligence can help predict how lung disease will progress in people with systemic sclerosis (scleroderma). Researchers will analyze CT scans from 1000 patients to see if certain patterns in the lungs can forecast worsening disease, develo…